Want to see CH:IDIA full AI Analyst Report?
IDIA Stock Chart & Stats
CHF6.16
CHF0.49(7.95%)
At close: 4:00 PM EDT
CHF6.16
CHF0.49(7.95%)
Day’s Range― - ―
52-Week RangeCHF2.42 - CHF7.56
Previous CloseN/A
Volume1.17M
Average Volume (3M)2.48M
Market Cap
CHF1.56B
Enterprise ValueCHF3.01K
Total Cash (Recent Filing)CHF88.69M
Total Debt (Recent Filing)CHF1.32B
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Oct 29, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding265,116,460
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF4.75Price Target Upside-22.89% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.57
Revenue Forecast (FY)CHF207.04M
Bulls Say, Bears Say
Bulls Say
High Gross MarginAn ~81% gross margin provides a structural profitability buffer common in small-molecule pharma: it enables scalable gross profits as sales grow, funds R&D or commercialization investment without a proportional rise in COGS, and is attractive to partners seeking high-margin products.
Diversified Revenue ModelIdorsia’s model mixes direct product sales with licensing, milestone and royalty income. That dual approach reduces single-product and geographic concentration risk, supports non-dilutive milestone funding, and provides multiple durable monetization paths as pipeline programs advance or are partnered.
Cash Losss Reflect Cash FlowFree cash flow tracking net loss (~1.04x) indicates accounting losses largely reflect cash consumption rather than large non-cash charges. This alignment improves transparency for financing and planning, making cash needs more predictable for securing durable funding or partner support.
Bears Say
Severely Stressed Balance SheetMaterially negative equity and ~1.32b of debt versus a small asset base sharply reduce financial flexibility. This elevated leverage raises refinancing and covenant risks, limits ability to invest in late-stage trials or launches, and increases dependence on external funding or dilution over months to years.
Persistent Cash BurnSustained negative operating and free cash flow (~-125m / -130m TTM) signals ongoing need for external financing. Persistent cash consumption constrains R&D and commercial ramp investments, increases dilution or debt reliance, and is a multi-quarter structural risk unless revenues or partner inflows reverse the trend.
Declining Revenue & Heavy LossesFalling revenue and extreme negative margins indicate the company is not covering fixed costs with current sales. Without durable revenue growth or successful pipeline commercialization, losses may persist, pressuring cash and forcing cost cuts or deal-making that could alter strategic priorities.
IDIA FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was CHF2.42 and its highest was CHF7.56 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF1.56B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 73 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Jul 30, 2026. The company reported -CHF0.165 earnings per share for the quarter, beating the consensus estimate of -CHF0.195 by CHF0.03.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Overvalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of N/A. See more information on Idorsia Ltd dividends here
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.27.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 265,116,460 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.165 in its last earnings report, beating expectations of -CHF0.195. Following the earnings report the stock price went down -4.962%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in CH:IDIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDIA Stock 12 Month Forecast
Average Price Target
CHF4.75
▼(-22.89% Downside)
Technical Analysis
Addex Therapeutics
―
Molecular Partners AG
―
Basilea Pharmaceutica
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―